Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€17.43

€17.43

1.210%
0.21
1.210%
-
 
03.02.26 / Tradegate WKN: A118WG / Name: CareDx / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Caredx Inc Stock

There is an upward development for Caredx Inc compared to yesterday, with an increase of €0.21 (1.210%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Caredx Inc stock. Negative votes have not been in the majority for any criteria for this stock

CareDx is a publicly traded biotechnology company that specializes in providing innovative transplant solutions for patients suffering from various diseases. The company has developed a range of diagnostic solutions that help doctors monitor the health of organ transplant recipients, including tests that can detect early signs of organ rejection. CareDx has a strong track record of developing cutting-edge medical technologies and working with leading healthcare providers to improve patient outcomes. As a publicly-listed company, CareDx has a diverse shareholder base and is subject to the scrutiny of regulatory bodies, providing transparency and accountability to investors.

Pros and Cons of Caredx Inc in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Caredx Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Caredx Inc 1.210% 0.490% 6.736% -23.080% 6.801% 13.595% -75.979%
Evolus Inc -1.940% -0.980% -29.123% -67.419% -25.872% -53.563% -28.343%
Madrigal Pharmaceuticals inc. -2.190% -1.827% -19.416% 29.159% -18.074% 54.697% 341.418%
Heron Therapeutics Inc. -1.610% -2.732% 8.796% -28.658% 5.476% -55.416% -92.260%

News

CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026: https://cdn.content.foolcdn.com/images/1umn9qeh/production/1a599f395be31e2f508c3aa7decb988f9ce983b7-1401x1251.png?w=1401&h=1251
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026

John Walter Hanna Jr., President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21 and Jan. 22, 2026, for a total value of approximately

CareDx President and CEO Sells 19,000 Shares for $412,000: https://cdn.content.foolcdn.com/images/1umn9qeh/production/6f699693a3501babe6eb40aac5d3061bf74bda96-1401x1251.png?w=1401&h=1251
CareDx President and CEO Sells 19,000 Shares for $412,000

John Hanna, President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21, 2026 and Jan. 22, 2026, with an aggregate transaction value of

CareDx (CDNA) EPS Beats Sales Gain 14%
CareDx (CDNA) EPS Beats Sales Gain 14%

CareDx (NASDAQ:CDNA), a molecular diagnostics company specializing in transplant care solutions, released its results for the second quarter of fiscal 2025 on August 6, 2025. The big news from the